Advancing host-directed therapy for tuberculosis

被引：229

作者：

Wallis, Robert S. ^{[1
]}

Hafner, Richard ^{[2
]}

机构：

[1] Aurum Inst, ZA-2193 Johannesburg, South Africa

[2] NIH, Div Aids, Bethesda, MD 20852 USA

来源：

NATURE REVIEWS IMMUNOLOGY | 2015年 / 15卷 / 04期

基金：

美国国家卫生研究院;

关键词：

TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; FACTOR MONOCLONAL-ANTIBODY; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; DOUBLE-BLIND; VITAMIN-D; HUMAN MACROPHAGES; FACTOR-ALPHA; INFECTION;

D O I：

10.1038/nri3813

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Improved treatments are needed for nearly all forms of Mycobacterium tuberculosis infection. Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment duration, prevent resistance and reduce lung injury by promoting autophagy, antimicrobial peptide production and other macrophage effector mechanisms, as well as by modifying specific mechanisms that cause lung inflammation and matrix destruction. The range of candidates is broad, including several agents approved for other clinical indications that are ready for evaluation in Phase II clinical trials. The promise of new and existing host-directed therapies that could accelerate response and improve tuberculosis treatment outcomes is discussed in this Opinion article.

引用

页码：255 / 263

页数：9

共 122 条

[1] Antibody-Mediated Immunity against Tuberculosis: Implications for Vaccine Development [J].